To assess the efficacy of different doses and dosing regimens of pelacarsen for reduction of plasma Lp(a) levels in participants with hyperlipoproteinaemia(a) and established cardiovascular disease (CVD)
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
